Potential Impact of Rapid Blood Culture Testing for Gram-Positive Bacteremia in Japan with the Verigene Gram-Positive Blood Culture Test.
Background.Early detection of Gram-positive bacteremia and timely appropriate antimicrobial therapy are required for decreasing patient mortality. The purpose of our study was to evaluate the performance of the Verigene Gram-positive blood culture assay (BC-GP) in two special healthcare settings and determine the potential impact of rapid blood culture testing for Gram-positive bacteremia within the Japanese healthcare delivery system. Furthermore, the study included simulated blood cultures, which included a library of well-characterized methicillin-resistantStaphylococcus aureus(MRSA) and vancomycin-resistant enterococci (VRE) isolates reflecting different geographical regions in Japan.Methods.A total 347 BC-GP assays were performed on clinical and simulated blood cultures. BC-GP results were compared to results obtained by reference methods for genus/species identification and detection of resistance genes using molecular and MALDI-TOF MS methodologies.Results.For identification and detection of resistance genes at two clinical sites and simulated blood cultures, overall concordance of BC-GP with reference methods was 327/347 (94%). The time for identification and antimicrobial resistance detection by BC-GP was significantly shorter compared to routine testing especially at the cardiology hospital, which does not offer clinical microbiology services on weekends and holidays.Conclusion.BC-GP generated accurate identification and detection of resistance markers compared with routine laboratory methods for Gram-positive organisms in specialized clinical settings providing more rapid results than current routine testing.
Department of Infectious Diseases, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan; Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan; Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Ken
0000-0002-3165-8206
K
Kikuchi
Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Mari
M
Matsuda
Department of Infectious Diseases, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan; Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Shigekazu
S
Iguchi
Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Tomonori
T
Mizutani
Department of Infection Control Science, Faculty of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan.
Keiichi
K
Hiramatsu
Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan.
Michiru
M
Tega-Ishii
Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan.
Kaori
K
Sansaka
Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan.
Kenta
K
Negishi
Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan.
Kimie
K
Shimada
Sakakibara Heart Institute, 1-16-1 Asahimachi, Fuchu, Tokyo 183-0003, Japan.
Jun
J
Umemura
Miroku Medical Laboratory Inc., 659-2 Innai, Saku, Nagano 384-2201, Japan.
Shigeyuki
S
Notake
Miroku Medical Laboratory Inc., 659-2 Innai, Saku, Nagano 384-2201, Japan.
Hideji
H
Yanagisawa
East-West Diagnostics/Theranostics, San Francisco, CA 94105, USA.
Hiroshi
0000-0001-5321-1299
H
Takahashi
Department of Infectious Diseases, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Reiko
R
Yabusaki
Department of Infectious Diseases, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Hideki
H
Araoka
Department of Infectious Diseases, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan.
Akiko
A
Yoneyama